Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Artificial intelligence could help pick the best embryos for IVF

NCT ID NCT07464275

Diagnosis Sponsor: Future Fertility Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an AI software called MAGENTA Blast that analyzes images of Day 3 embryos to predict which ones will develop into blastocysts by Day 5. Researchers looked at data from 76 women undergoing IVF to see if the tool could help embryologists make better decisions about which embryos to transfer or freeze. The goal is to improve success rates in fertility treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MAGENTA Blast (AI software device)
What this could lead to
If validated, this AI tool could help embryologists choose the best embryos for IVF, potentially improving pregnancy success rates.
What could go wrong
This is a small, retrospective study (76 participants) that only tests prediction accuracy, not actual pregnancy outcomes. The tool may not work as well in real-time use or with different patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

76 people

The number who actually took part.

Started

Apr 2026

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women undergoing fresh IVF treatment

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women undergoing fresh IVF treatment using their own eggs * At least 18 years of age * Total antral follicle count (AFC) of at least 12 as measured by ultrasound prior to stimulation (in cases where AFC is performed) * Basal day 3 follicle-stimulating hormone levels (FSH) \< 10 IU (in cases where basal day 3 FSH is performed) * At least 8 normally fertilized eggs at the pronuclear (2PN) stage * Fertilization using only ejaculated sperm (fresh or frozen) - no surgically removed sperm * At least one two-cell embryo on Day 3 * At least part of the embryo cohort is cultured until day 5 (i.e. 114-116 HPI) Exclusion Criteria: * Use of re-inseminated eggs (rescue ICSI) * Gestational carriers * Concurrent participation in another clinical study * Previous enrollment in this clinical study (i.e., one cycle data per patient) * History of cancer * Planned Day 3 laser-assisted hatching or embryos that underwent Day 3 biopsy for preimplantation genetic testing (PGT) * Low quality images * Lack of correlating reproductive outcomes (IVF lab results not available)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fertility disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fertility disorders Infertility

Contacts and locations

Locations

  • Future Fertility

    Toronto, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.